---
title: "Trulicity (dulaglutide) in type 2 diabetes: Safety questions"
description: "Safety questions on Trulicity (dulaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What are the long-term side effects of Trulicity (REWIND, 5.4 years)? What are the most common side effects of Trulicity? What are the side effects of Trulicity 3 mg and 4.5 mg? How common are nausea and stomach side effects with Trulicity? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide) in type 2 diabetes: Safety questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)

Safety questions that apply to every indication of Trulicity are on [Trulicity (dulaglutide), all indications: Safety](https://www.evicenter.com/medical-information/trulicity/safety).

## Side effects

<a id="trulicity-rewind-safety"></a>

### What are the long-term side effects of Trulicity (REWIND, 5.4 years)?

Applies to: Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors

> “The safety profile of Trulicity was consistent with the GLP-1 receptor agonist class.<sup>2</sup> The most common adverse events leading to the discontinuation of Trulicity were gastrointestinal events.<sup>15</sup>”

Source: [TRULICITY: Trulicity for Cardiovascular | REWIND Trial, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight/cardiovascular-disease#:~:text=The%20safety%20profile%20of%20Trulicity,discontinuation%20of%20Trulicity%20were%20gastrointestinal)

> “In a cardiovascular outcomes trial with a median follow up of 5.4 years involving patients with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors, diabetic retinopathy complications occurred in patients treated with TRULICITY 1.5 mg (1.9%) and placebo (1.5%). These events were prospectively ascertained as a secondary composite endpoint. The proportion of patients with diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (TRULICITY 8.5%, placebo 6.2%) than among patients without a known history of diabetic retinopathy (TRULICITY 1%, placebo 1%).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20a%20cardiovascular%20outcomes%20trial%20with,retinopathy%20%28TRULICITY%201%25%2C%20placebo%201%25%29.)

> “In a cardiovascular outcomes trial in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors with a median follow up of 5.4 years [see Clinical Studies 14.5], cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20a%20cardiovascular%20outcomes%20trial%20in,on%20TRULICITY%20and%20placebo%20respectively.)

Note: REWIND had a median follow-up of 5.4 years. The first passage is from the cardiovascular page of the Trulicity HCP site; the others are from the Warnings and Precautions and Adverse Reactions sections of the Prescribing Information.

<a id="trulicity-side-effects"></a>

### What are the most common side effects of Trulicity?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Most common adverse reactions (incidence ≥5%) are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (6.1).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Most%20common%20adverse%20reactions%20%28incidence,pain%2C%20and%20decreased%20appetite%20%286.1%29.)

> “Table 1 shows adverse reactions, excluding hypoglycemia, occurring in ≥5% of TRULICITY treated adult patients and more commonly than placebo in a pool of placebo-controlled trials.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%201%20shows%20adverse%20reactions%2C,a%20pool%20of%20placebo%2Dcontrolled%20trials.)

> “Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus
>
> a Includes diarrhea, fecal volume increased, frequent bowel movements.
>
>
>
>
> b Includes retching, vomiting, vomiting projectile.
>
>
>
>
> c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.
>
>
>
>
> d Includes fatigue, asthenia, malaise.
>
>
>
>
> Note: Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.
>
>
> Adverse Reaction	Placebo
> (N=568)
> %	TRULICITY 0.75 mg
> (N=836)
> %	TRULICITY 1.5 mg
> (N=834)
> %
> Nausea	5.3	12.4	21.1
> Diarrheaa	6.7	8.9	12.6
> Vomitingb	2.3	6.0	12.7
> Abdominal Painc	4.9	6.5	9.4
> Decreased Appetite	1.6	4.9	8.6
> Dyspepsia	2.3	4.1	5.8
> Fatigued	2.6	4.2	5.6”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%201%3A%20Adverse%20Reactions%20in,5.6)

Note: The first passage is from the Highlights of the Prescribing Information, which list five reactions; Table 1 also lists dyspepsia and fatigue at 5% or more with TRULICITY 1.5 mg. Table 1 columns are placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, in that order (% of patients).

<a id="trulicity-side-effects-higher-doses"></a>

### What are the side effects of Trulicity 3 mg and 4.5 mg?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Table 2 shows adverse reactions occurring ≥5% in any of the treatment groups through 36 weeks in a clinical trial with 1842 adult patients with type 2 diabetes mellitus treated with TRULICITY 1.5 mg, 3 mg, or 4.5 mg subcutaneously once weekly as an add-on to metformin [see Clinical Studies (14.3)]. The adverse reaction profile is consistent with previous clinical trials in adults.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%202%20shows%20adverse%20reactions,previous%20clinical%20trials%20in%20adults.)

> “Table 2: Adverse Reactions That Occurred in ≥5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeksa
>
> a Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.
>
>
> Adverse Reaction	TRULICITY 1.5 mg
> (N=612)
> %	TRULICITY 3 mg
> (N=616)
> %	TRULICITY 4.5 mg
> (N=614)
> %
> Nausea	13.4	15.6	16.4
> Diarrhea	7.0	11.4	10.7
> Vomiting	5.6	8.3	9.3
> Dyspepsia	2.8	5.0	2.6”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%202%3A%20Adverse%20Reactions%20That,2.6)

> “Discontinuation rates due to GI adverse events through 36 weeks<sup>*5</sup>
>
> Trulicity 1.5 mg (n=612)
>
> Trulicity 3.0 mg (n=616)
>
> Trulicity 4.5 mg (n=614)
>
> Discontinuing treatment due to GI adverse event,% (n)	1.1% (7)	3.1% (19)	3.1% (19)
>
> <sup>*</sup>Data included only the most common GI-related AEs (nausea, diarrhea, vomiting, dyspepsia).”

Source: [TRULICITY: Clinical Trials: Lowereing A1C, Weight Change & CV Data | HCP, captured 2026-11-13](https://trulicity.lilly.com/hcp/efficacy-weight#:~:text=View%20image%20descriptions-,Discontinuation%20rates%20due%20to%20GI%20adverse%20events%20through%2036,AEs%20%28nausea%2C%20diarrhea%2C%20vomiting%2C%20dyspepsia%29.)

Note: Table 2 columns are TRULICITY 1.5 mg, 3 mg, and 4.5 mg, in that order. The discontinuation table is from the clinical data page of the Trulicity HCP site.

<a id="trulicity-gi-side-effects"></a>

### How common are nausea and stomach side effects with Trulicity?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In the pool of placebo-controlled trials, gastrointestinal (GI) adverse reactions occurred more frequently among patients who received TRULICITY compared to patients who received placebo (placebo 21%, 0.75 mg 32%, 1.5 mg 41%). A higher percentage of patients who received TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to GI adverse reactions than patients who received placebo (0.2%). Investigators graded the severity of GI adverse reactions that occurred in those treated with 0.75 mg and 1.5 mg of TRULICITY as “mild” in 58% and 48% of cases, respectively, “moderate” in 35% and 42% of cases, respectively, or “severe” in 7% and 11% of cases, respectively.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20the%20pool%20of%20placebo%2Dcontrolled%20trials%2C%20gastrointestinal,and%2011%25%20of%20cases%2C%20respectively.)

> “The following GI adverse reactions were reported more frequently in TRULICITY-treated patients than placebo -treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20following%20GI%20adverse%20reactions,and%20eructation%20%280.2%25%2C%200.6%25%2C%201.6%25%29.)

> “Nausea	5.3	12.4	21.1”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Nausea-,5.3,21.1)

Note: The last passage is the nausea row of Table 1: placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg (% of adult patients).

<a id="trulicity-reduce-gi-side-effects"></a>

### How can Trulicity stomach side effects be reduced?

Applies to: Glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20recommended%20starting%20dosage%20of,%285.6%29%20and%20Adverse%20Reactions%20%286.1%29%5D.)

> “If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=If%20additional%20glycemic%20control%20is%20needed%2C%20increase%20the%20dosage%20to,%285.6%29%20and%20Adverse%20Reactions%20%286.1%29%5D.)

> “Inform patients of the potential risk of severe gastrointestinal adverse reactions. Instruct patients to contact their healthcare provider if they have severe or persistent gastrointestinal symptoms [see Warnings and Precautions (5.6)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Inform%20patients%20of%20the%20potential%20risk%20of%20severe,%5Bsee%20Warnings%20and%20Precautions%20%285.6%29%5D.)

<a id="trulicity-hypoglycemia"></a>

### Does Trulicity cause low blood sugar?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Patients receiving TRULICITY in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1) and Drug Interactions (7)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Patients%20receiving%20TRULICITY%20in%20combination,%286.1%29%20and%20Drug%20Interactions%20%287%29%5D.)

> “Table 3: Incidence (%) of Hypoglycemia in Adult Patients with Type 2 Diabetes Mellitus in Placebo-Controlled Trials
> 	Placebo	TRULICITY 0.75 mg	TRULICITY 1.5 mg
> Add-on to Metformin
>       (26 weeks)	N=177	N=302	N=304
>      Hypoglycemia with a glucose level <54 mg/dL	0	0.3	0.7
>      Severe hypoglycemia	0	0	0
> Add-on to Metformin + Pioglitazone
>       (26 weeks)	N=141	N=280	N=279
>      Hypoglycemia with a glucose level <54 mg/dL	1.4	2.1	0
>      Severe hypoglycemia	0	0	0
> Add-on to Glimepiride
>       (24 weeks)	N=60	-	N=239
>      Hypoglycemia with a glucose level <54 mg/dL	0	-	3.3
>      Severe hypoglycemia	0	-	0
> In Combination with Insulin Glargine ± Metformin
>       (28 weeks)	N=150	-	N=150
>      Hypoglycemia with a glucose level <54 mg/dL	9.3	-	14.7
>      Severe hypoglycemia	0	-	0.7
> Add-on to SGLT2i ± Metformin
>       (24 weeks)	N=140	N=141	N=142
>      Hypoglycemia with a glucose level <54 mg/dL	0.7	0.7	0.7
>      Severe hypoglycemia	0	0.7	0”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%203%3A%20Incidence%20%28%25%29%20of,0)

> “Hypoglycemia was more frequent when TRULICITY was used in combination with a sulfonylurea or insulin than when used with non-secretagogues. In a 78-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. Severe hypoglycemia occurred in 0% and 0.7% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. In a 52-week adult clinical trial, hypoglycemia (glucose level <54 mg/dL) occurred in 77% and 69% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Severe hypoglycemia occurred in 2.7% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Refer to Table 3 for the incidence of hypoglycemia in patients treated in combination with basal insulin glargine.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Hypoglycemia%20was%20more%20frequent%20when,combination%20with%20basal%20insulin%20glargine.)

Note: Table 3 columns are placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, in that order (% of patients).

<a id="trulicity-injection-site-reactions"></a>

### How common are injection site reactions with Trulicity?

Applies to: Glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20the%20placebo%2Dcontrolled%20studies%20in,in%200.0%25%20of%20placebo%2Dtreated%20patients.)

> “The safety profile in pediatric patients treated with TRULICITY 0.75 mg and 1.5 mg subcutaneously once-weekly was consistent with that described above for adult patients with type 2 diabetes mellitus with the exception of injection site reactions. In pediatric patients, the incidence of injection site reactions was 3.9% (2 patients) in the TRULICITY 0.75 mg group, 3.8% (2 patients) in the TRULICITY 1.5 mg group, and 2.0% (1 patient) in the placebo group.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20safety%20profile%20in%20pediatric,patient%29%20in%20the%20placebo%20group.)

<a id="trulicity-heart-rate"></a>

### Does Trulicity increase heart rate?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In adult patients, TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20adult%20patients%2C%20TRULICITY%200.75,2%2D4%20beats%20per%20minute%20%28bpm%29.)

> “Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY. Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Adverse%20reactions%20of%20sinus%20tachycardia,with%20placebo%2C%20TRULICITY%200.75%20mg%20and%20TRULICITY%201.5%20mg%2C%20respectively.)

<a id="trulicity-ecg-pr-qt"></a>

### Does Trulicity affect the ECG (PR interval and QTc)?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated adult patients in contrast to a mean decrease of 0.9 milliseconds in placebo-treated patients. The adverse reaction of first-degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively). On electrocardiograms, a PR interval increase to at least 220 milliseconds was observed in 0.7%, 2.5% and 3.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=A%20mean%20increase%20from%20baseline,and%20TRULICITY%201.5%20mg%2C%20respectively.)

> “The effect of dulaglutide on cardiac repolarization was tested in a thorough QTc study. Dulaglutide did not produce QTc prolongation at doses of 4 and 7 mg. The maximum recommended dose is 4.5 mg once weekly.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20effect%20of%20dulaglutide%20on,is%204.5%20mg%20once%20weekly.)

## Related pages
- [Medical information: Trulicity (dulaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/guidelines)
